Wellington Biomedical Innovation Master Investors (Cayman) I L.P. - 02 Aug 2021 Form 4 Insider Report for Nuvalent, Inc. (NUVL)

Role
10%+ Owner
Signature
Wellington Biomedical Innovation Master Investors (Cayman) I L.P. By: Wellington Management Company LLP, as Investment Adviser /s/ Jennifer Boylan Title: Authorized Person
Issuer symbol
NUVL
Transactions as of
02 Aug 2021
Net transactions value
$0
Form type
4
Filing time
03 Aug 2021, 20:01:28 UTC
Previous filing
28 Jul 2021
Next filing
09 Nov 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NUVL Class A Common Stock Conversion of derivative security +897,671 897,671 02 Aug 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NUVL Series B Preferred Stock Conversion of derivative security $0 -4,831,384 -100% $0.000000* 0 02 Aug 2021 Class A Common Stock 897,671 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Wellington Biomedical Innovation Master Investors (Cayman) I L.P. is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Upon the closing of the Issuer's initial public offering, each share of Series B Preferred Stock automatically converted into 0.1858 shares of the Issuer's Class A Common Stock. The Series B Preferred Stock had no expiration date.